Avoro Capital Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Avoro Capital Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,140,607	Closed	-$37.4M	–	49
2024 Q1	$37.4M	Buy	4,140,607 +990,607	+31%	+$9.63M	0.44%	38
2023 Q4	$34.2M	Hold	3,150,000	–	–	0.47%	29
2023 Q3	$25.4M	Hold	3,150,000	–	–	0.4%	29
2023 Q2	$34.2M	Hold	3,150,000	–	–	0.46%	27
2023 Q1	$21.7M	Hold	3,150,000	–	–	0.32%	29
2022 Q4	$12.5M	Hold	3,150,000	–	–	0.19%	33
2022 Q3	$20.9M	Hold	3,150,000	–	–	0.39%	31
2022 Q2	$15.2M	Hold	3,150,000	–	–	0.3%	32
2022 Q1	$29.5M	Sell	3,150,000 -85,000	-3%	-$844K	0.54%	29
2021 Q4	$38.4M	Hold	3,235,000	–	–	0.65%	24
2021 Q3	$36.8M	Hold	3,235,000	–	–	0.58%	26
2021 Q2	$58M	Hold	3,235,000	–	–	1.01%	23
2021 Q1	$50.1M	Buy	3,235,000 +2,858	+0.1%	+$41.3K	0.86%	24
2020 Q4	$39.4M	Buy	3,232,142 +232,142	+8%	+$3.24M	0.68%	27
2020 Q3	$38.5M	Buy	3,000,000 +10,000	+0.3%	+$86.3K	0.55%	28
2020 Q2	$30.4M	Buy	2,990,000 +1,440,000	+93%	+$13.2M	0.6%	30
2020 Q1	$12.6M	Hold	1,550,000	–	–	0.42%	31
2019 Q4	$13.4M	Buy	+1,550,000	New	+$8.7M	0.39%	25

Other funds holding MRNS

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avoro Capital Advisors's MRNS Position: Q2 2024 in Review

Avoro Capital Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 4,140,607 shares — an estimated $37.4M sold.

Avoro Capital Advisors first reported a position in MRNS in Q4 2019 and held it in 18 quarters. The position peaked at $58M in Q2 2021. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

Avoro Capital Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
Avoro Capital Advisors sold 4,140,607 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $37.4M.
Avoro Capital Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q4 2019 and held it in 18 quarters.
Avoro Capital Advisors's Marinus Pharmaceuticals, Inc position peaked at $58M in Q2 2021.
90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Avoro Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.